GlaxoSmithKline: collaboration with AI firm Exscientia.

(CercleFinance.com) - GlaxoSmithKline has entered into a strategic collaboration with Exscientia, a British company focused on artificial intelligence (AI)-driven drug discovery.


Exscientia said it plans to combine its platform with GSK's expertise in order to discover novel and selective small molecules for up to 10 disease-related targets chosen by the biopharmaceutical firm.

Exscientia will receive research payments, along with milestone payments if all objectives are met, with a total amount payable by GSK on achieving these milestones reaching 33 million pounds (around 37 million euros), if all 10 projects are advanced.

No further financial details have been disclosed.

Exscientia is already collaborating with Germany's Evotec in immuno-oncology and France's Sanofi in metabolic diseases.

Copyright (c) 2017 CercleFinance.com. All rights reserved.